Continue ACE inhibitors and ARBs in reduced GFR - it has CV benefits
Continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with the cardiovascular benefit.
US: Chronic kidney disease (CKD) independently increases the risk of death and cardiovascular disease (CVD) in the general population. The participants with an estimated glomerular filtration rate (eGFR) decline have a significantly higher risk of all‐cause mortality and cardiovascular events even after adjustment for baseline covariates including the initial eGFR.
The certainty of using drugs that block the renin-angiotensin system in such patients whose estimated GFR is low is been a question. To uncover these researchers from Pennsylvania conducted a retrospective cohort study that was published in JAMA Internal Medicine.
Continuing angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in patients with declining kidney function may deliver cardiovascular benefits without increasing the risk of end-stage kidney disease (ESKD), according to the study.
The retrospective cohort study included 3909 individuals who had initiated ACE-I or ARB therapy and had experienced estimated glomerular filtration rate (eGFR) decrease to <30 mL/min/1.73m2 during therapy. The study was started on 1 January 2004 continued till 25 January 2019. Findings of the study were:
a)Of the 3909 individuals receiving ACE-I or ARB treatment who experienced an eGFR decrease to below 30 mL/min/1.73 m2 female; mean age, 73.7, 1235 discontinued ACE-I or ARB therapy within 6 months after the eGFR decrease and 2674 did not discontinue therapy.
b)A total of 434 patients who discontinued ACE-I or ARB therapy and 786 who did not discontinue therapy died during a median follow-up of 2.9 years.
c)Among the sample, patients who discontinued ACE-I or ARB therapy were associated with a higher risk of mortality (hazard ratio [HR], 1.39; and MACE (HR, 1.37; ), but no statistically significant difference in the risk of ESKD was found.
The authors concluded the findings suggest continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with the cardiovascular benefit without excessive harm of ESKD.
For further reading click on the following link,
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.